表紙
市場調查報告書

骨質疏鬆症市場·預測分析

Osteoporosis Market and Forecast Analysis

出版商 Datamonitor Healthcare 商品編碼 498958
出版日期 內容資訊 英文 212 Pages
商品交期: 最快1-2個工作天內
價格
骨質疏鬆症市場·預測分析 Osteoporosis Market and Forecast Analysis
出版日期: 2019年01月02日內容資訊: 英文 212 Pages
簡介

本報告提供骨質疏鬆症的已上市藥物及開發平台趨勢,彙整疾病概要,地區/各主要國家的患者數的變化與預測,主要的已上市藥物簡介,開發平台趨勢等資料。

流行病學:骨質疏鬆症

  • 摘要整理
  • 疾病的背景
  • 資訊來源·調查手法
  • 預測:骨質缺乏症
  • 預測:骨質疏鬆症
  • 流行病學者的考察
  • 優勢·規定
  • 附錄

已上市藥物:骨質疏鬆症

  • 摘要整理
  • 產品概要
  • 雙磷酸鹽
  • 雌激素·SERM
  • 抑鈣素
  • 其他藥劑級
  • 產品簡介: Forteo
  • 產品簡介: Prolia

開發平台:骨質疏鬆症

  • 摘要整理
  • 臨床實驗平台:概要
  • 比較儀治療
  • 近幾年中止的藥物
  • 產品簡介 (後期): Evenity
  • 產品簡介 (後期): abaloparatide

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4728

OVERVIEW:

Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture.

MARKET SNAPSHOT:

  • Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU.
  • The oral bisphosphonate alendronate dominates the treatment of all severities of low bone mass.
  • Forecasted growth in the total prevalence of osteopenia and osteoporosis will be driven by aging populations.
  • Biosimilar erosion and new anabolic entrants with superior efficacy are set to erode Forteo's blockbuster sales.
  • The arrival of Amgen's Evenity will be delayed due to safety issues.

TABLE OF CONTENTS

FORECAST: OSTEOPOROSIS (Published on 31 May 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • ACTONEL (RISEDRONATE)
  • BONIVA (IBANDRONATE)
  • DUAVEE ([CONJUGATED ESTROGENS + BAZEDOXIFENE])
  • EDIROL (ELDECALCITOL)
  • EVENITY (ROMOSOZUMAB)
  • EVISTA (RALOXIFENE)
  • FORTEO (TERIPARATIDE) AND MOVYMIA (TERIPARATIDE)
  • FOSAMAX (ALENDRONATE)
  • PROLIA (DENOSUMAB)
  • RECLAST (ZOLEDRONIC ACID)
  • TYMLOS (ABALOPARATIDE)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: OSTEOPOROSIS (Published on 23 March 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • TREATMENT TRENDS IN OSTEOPENIA
  • TREATMENT TRENDS IN OSTEOPOROSIS
  • TREATMENT TRENDS IN SEVERE OSTEOPOROSIS
  • COMPLIANCE RATES
  • UNMET NEEDS IN OSTEOPOROSIS

EPIDEMIOLOGY: OSTEOPOROSIS (Published on 02 January 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST: OSTEOPENIA
  • FORECAST: OSTEOPOROSIS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: OSTEOPOROSIS (Published on 09 March 2018)

  • OVERVIEW
  • PRODUCT OVERVIEW
  • BISPHOSPHONATES
  • ESTROGENS AND SERMS
  • CALCITONIN
  • ANABOLIC THERAPIES
  • OTHER DRUG CLASSES
  • PRODUCT PROFILE: FORTEO
  • PRODUCT PROFILE: PROLIA
  • PRODUCT PROFILE: TYMLOS

PIPELINE: OSTEOPOROSIS (Published on 09 March 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • COMPARATOR THERAPY
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): EVENITY

LIST OF FIGURES

  • Figure 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Osteoporosis sales in the US, by class, 2016-25
  • Figure 3: Osteoporosis sales for Edirol, generic eldecalcitol, Forteo, and Evenity in Japan, by product, 2016-25
  • Figure 4: Osteoporosis sales for Forteo, Movymia, biosimilar teriparatide, Evenity, and Tymlos across the US, Japan, and five major EU markets, 2016-25
  • Figure 5: Osteoporosis sales for branded and generic bisphosphonates across the US, Japan, and five major EU markets, 2016-25
  • Figure 6: Patient-based forecast methodology for osteoporosis
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 9: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 10: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country, 2016-25
  • Figure 12: Duavee sales for osteoporosis across the US and Italy, by country, 2016-25
  • Figure 13: Edirol sales for osteoporosis in Japan, 2016-25
  • Figure 14: Generic eldecalcitol sales for osteoporosis in Japan, 2016-25
  • Figure 15: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 17: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 18: Movymia sales for osteoporosis across the five major EU markets, by country, 2016-25
  • Figure 19: Biosimilar teriparatide sales for osteoporosis in the US, 2016-25
  • Figure 20: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 21: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 22: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 23: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 24: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 25: Tymlos sales for osteoporosis across the US and five major EU markets, by country, 2016-25
  • Figure 26: Percentage of patients with low bone mass diagnosed at each disease subtype for the US, Japan, and five major EU markets
  • Figure 27: Segmentation of patients suffering from low bone mass in the US, Japan, and five major EU markets, by disease severity and country
  • Figure 28: Percentage of patients receiving each line of therapy, by severity
  • Figure 29: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteopenia, by country
  • Figure 30: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteopenia, by country
  • Figure 31: Top three first-line treatment regimens for osteopenia patients, by country
  • Figure 32: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteoporosis, by country
  • Figure 33: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteoporosis, by country
  • Figure 34: Top three first-line treatment regimens for osteoporosis patients, by country
  • Figure 35: Top three second-line treatment regimens for osteoporosis patients, by country
  • Figure 36: Top three third-line treatment regimens for osteoporosis patients, by country
  • Figure 37: Top three first-line treatment regimens for severe osteoporosis patients, by country
  • Figure 38: Top three second-line treatment regimens for severe osteoporosis patients, by country
  • Figure 39: Percentage of diagnosed patients receiving each class of pharmacological therapy for the third-line treatment of severe osteoporosis, by country
  • Figure 40: Compliance rates of patients suffering from low bone mass in the US, Japan, and five major EU markets, by country and disease subtype
  • Figure 41: Key unmet needs in osteoporosis treatment across the US, Japan, and five major EU markets
  • Figure 42: Trends in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 43: Trends in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 44: Forteo for osteoporosis - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis
  • Figure 47: Prolia for osteoporosis - SWOT analysis
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • Figure 50: Tymlos for osteoporosis - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Tymlos for osteoporosis
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Tymlos for osteoporosis
  • Figure 53: Evenity for osteoporosis - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis

LIST OF TABLES

  • Table 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Osteoporosis sales in the US, by brand and class ($m), 2016-25
  • Table 3: Osteoporosis sales in Japan, by brand and class ($m), 2016-25
  • Table 4: Osteoporosis sales in the five major EU markets, by brand and class ($m), 2016-25
  • Table 5: Summary of drug classes and molecules in Datamonitor Healthcare's osteoporosis patient-based forecast
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Patent expiry dates for key marketed brands in osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 8: Estimated launch dates for key late-stage osteoporosis pipeline candidates in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 9: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 10: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 11: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country ($m), 2016-25
  • Table 13: Duavee sales for osteoporosis across the US and Italy, by country ($m), 2016-25
  • Table 14: Edirol sales for osteoporosis in Japan ($m), 2016-25
  • Table 15: Generic eldecalcitol sales for osteoporosis in Japan ($m), 2016-25
  • Table 16: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 17: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 19: Movymia sales for osteoporosis across the five major EU markets, by country ($m), 2016-25
  • Table 20: Biosimilar teriparatide sales for osteoporosis in the US ($m), 2016-25
  • Table 21: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 22: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 23: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 24: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 25: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 26: Tymlos sales for osteoporosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 27: Physicians surveyed for the osteoporosis primary research study, 2016
  • Table 28: Physicians surveyed for the osteoporosis primary research study, 2016
  • Table 29: World Health Organization definitions of bone mass based on BMD
  • Table 30: Clinical risk factors included in FRAX scoring
  • Table 31: Selected bisphosphonates products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • Table 32: Selected SERMs and estrogen products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • Table 33: Calcitonin products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • Table 34: Other drugs available for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • Table 35: Low bone mass patients treated with pharmacological therapy in the US, Japan, and five major EU markets, by country (%)
  • Table 36: Top three third-line treatment regimens for osteopenia patients, by country (%)
  • Table 37: Sources used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
  • Table 38: Total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 39: Total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 40: Key marketed drugs for osteoporosis
  • Table 41: Bisphosphonate class overview
  • Table 42: Estrogens/SERMs class overview
  • Table 43: Salmon calcitonin class overview
  • Table 44: Anabolic class overview
  • Table 45: Other drug classes overview
  • Table 46: Forteo drug profile
  • Table 47: Forteo pivotal trial data in osteoporosis
  • Table 48: Forteo late-phase trial data in osteoporosis
  • Table 49: Prolia drug profile
  • Table 50: Prolia pivotal trial data in osteoporosis
  • Table 51: Prolia late-phase trial data in osteoporosis
  • Table 52: Tymlos drug profile
  • Table 53: Tymlos Phase III trial data in osteoporosis
  • Table 54: Tymlos planned Phase III trials in osteoporosis
  • Table 55: Phase III pipeline products in development for osteoporosis
  • Table 56: Forteo drug profile
  • Table 57: Forteo trial data in osteoporosis
  • Table 58: Late-stage compounds that were recently discontinued for osteoporosis
  • Table 59: Odanacatib drug profile
  • Table 60: Odanacatib trial data in osteoporosis
  • Table 61: Evenity drug profile
  • Table 62: Evenity pivotal trial data in osteoporosis
  • Table 63: Evenity other late-phase trials in osteoporosis